Table 2. Characteristics of the individuals involved in the measurement of poly(ADP-ribose) polymerase (PARP)-1 mRNA expression in peripheral blood mononuclear cells.
| Characteristic | Non-smoking controls (n = 10) | Non-obstructive smokers (n = 12) | Mild COPD(n = 4) | Moderate COPD (n = 14) | Severe COPD (n = 24) | Very severeCOPD (n = 21) | COPD exacerbation (n = 22) | p-value* |
| Age | 64.0±3.4 | 61.1±3.3 | 76.8±3.0 | 67.6±2.4 | 68.8±2.5 | 70.6±2.5 | 70.0±2.3 | 0.098 |
| Male | 7 (70.0%) | 7 (58.3%) | 4 (100.0%) | 13 (92.9%) | 22 (91.7%) | 21 (100.0%) | 20 (90.9%) | 0.009 |
| BMI | 25.7±1.6 | 27.4±2.0 | 23.4±1.7 | 24.3±1.4 | 25.9±0.9 | 23.3±1.2 | 23.4±0.9 | 0.17 |
| Smoking (pack-years) | - | 34.4±10.4 | 56.3±20.5 | 42.4±15.5 | 39.2±22.9 | 39.4±22.6 | 43.1±23.5 | 0.37 |
| Current smoker | - | 7 (58.3%) | 2 (50.0%) | 9 (64.3%) | 11 (45.8%) | 8 (38.1%) | 9 (40.9%) | 0.65 |
| Ex-smoker | - | 5 (41.7%) | 2 (50.0%) | 5 (35.7%) | 13 (54.1%) | 12 (57.1%) | 13 (59.1%) | 0.75 |
| FEV1, % of predicted | 97.6±4.5 | 81.0±5.6 | 94.5±9.0 | 60.8±2.6 | 39.0±1.5 | 24.2±1.0 | 33.1±2.9 | <0.001 |
Data are presented as mean ± SEM or n (%). *To test the equality of the data across the study groups, Kruskal-Wallis test and Pearson’s chi-square test was applied for numeric and nominal variables, respectively; in case of smoking-related variables, non-smoking controls were omitted from the analysis.